EDN1 and cardiovascular disorder: In addition to the improved lipid profile, affron® administration significantly reduced the circulating levels of ET-1, a potent vasoconstrictor peptide produced by the vascular endothelium that favors the development of cardiovascular diseases such as hypertension.